Oric Pharmaceuticals (ORIC) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Oric Pharmaceuticals (ORIC) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, losing 36.7% versus a loss of 50.0%. Over five years, SNDX leads with a -47.1% price change compared with -48.6% for ORIC. Syndax Pharmaceuticals is the larger company by market cap ($785.0 million vs $764.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORIC | SNDX |
|---|---|---|
| Share price | $7.36 | $8.72 |
| Market cap | $764.94M | $785.05M |
| 1-day change | -4.42% | -4.49% |
| YTD return | -10.02% | -58.50% |
| 1-year return | -36.66% | -50.00% |
| 5-year return | -48.64% | -47.09% |
| EPS (TTM) | $-1.44 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $172.35M |
| Revenue growth (YoY) | — | +627.84% |
| Net income (latest FY) | $-129.47M | $-285.42M |
| Operating margin | — | -158.45% |
| Net margin | — | -165.60% |
| 52-week high | $14.68 | $25.59 |
| 52-week low | $7.23 | $8.41 |
| Distance from 52-week high | -49.86% | -65.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +194.97% | +306.54% |
| Average volume | 1.59M | 2.63M |
| Shares outstanding | 103.93M | 90.03M |
| Employees | 111 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORIC has outperformed SNDX by 13.3 percentage points over the past year.
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
ORIC vs SNDX FAQ
Which is bigger, Oric Pharmaceuticals or Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) is larger, with a market capitalization of $785.05M compared with $764.94M for Oric Pharmaceuticals (ORIC).
Which stock has performed better over the past year, ORIC or SNDX?
ORIC returned -36.66% over the past 12 months, compared with -50.00% for SNDX (price return, excluding dividends). Past performance does not predict future results.
Are Oric Pharmaceuticals and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.